Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16650449 | 1.00 | BRD4 (0.36) | BRD4CREBBPEGFRFGFR1BRDT | |
| SCHEMBL16650793 | 0.94 | BRD4 (0.37) | BRD4CREBBPBRDTALDH1A1HSD17B10 | |
| SCHEMBL29848717 | 0.89 | CREBBP (0.47) | BRD4CREBBP | |
| SCHEMBL16650869 | 0.89 | CREBBP (0.47) | BRD4CREBBP | |
| SCHEMBL16651201 | 0.86 | CREBBP (0.37) | BRD4CREBBPHPGDHSD17B10 | |
| SCHEMBL29848696 | 0.86 | CREBBP (0.37) | BRD4CREBBPHPGDHSD17B10 | |
| SCHEMBL16651461 | 0.86 | BRD4 (0.37) | BRD4CREBBPBRDTKDM4EALDH1A1 | |
| SCHEMBL29848918 | 0.86 | BRD4 (0.37) | BRD4CREBBPBRDTKDM4EALDH1A1 | |
| SCHEMBL16650991 | 0.82 | BRD4 (0.43) | BRD4ALDH1A1HSD17B10 | |
| SCHEMBL16651194 | 0.82 | CREBBP (0.48) | BRD4CREBBPFGFR1CCNB2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3640241-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885CREBBP 45/4885EGFR 2193/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885CREBBP 45/4885EGFR 2193/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885CREBBP 45/4885EGFR 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.